SCHEMBL4259286

SCHEMBL4259286

CC(C)(C)OC(=O)N1CCC(=Cc2ccccc2C(F)(F)F)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.46
GPR119 Q8TDV5 2/20 0.43
SFRP1 Q8N474 1/20 0.43
TNF P01375 1/20 0.43
IL6 P05231 1/20 0.43
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ESR2 Q92731 1/20 0.41
TACR1 P25103 1/20 0.41
NFKB1 P19838 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
PDK2 Q15119 1/20 0.40
RORC P51449 1/20 0.40
EPHX2 P34913 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3951674 0.87 NFKB1 (0.46) GPR119TNFIL6MAPTMEN1
SCHEMBL16825145 0.85 GRM5 (0.47) GRM5GPR119MAPTMEN1KMT2A
SCHEMBL23148980 0.84 MAPT (0.47) GRM5GPR119SFRP1MAPTESR2
SCHEMBL29849674 0.84 MAPT (0.47) GRM5GPR119SFRP1MAPTESR2
SCHEMBL18280141 0.84 MAPT (0.47) GRM5GPR119SFRP1MAPTESR2
SCHEMBL4252698 0.83 TNF (0.48) TNFIL6MEN1KMT2ANFKB1
SCHEMBL7971750 0.82 ESR2 (0.48) GRM5GPR119MAPTMEN1KMT2A
SCHEMBL6382839 0.82 GRM5 (0.47) GRM5GPR119ESR2CHRM2CHRM4
SCHEMBL15057408 0.81 GPR119 (0.47) GRM5GPR119MEN1KMT2AESR2
SCHEMBL23119402 0.81 SRD5A2 (0.51) GRM5GPR119ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed
US-20090291955-A1 Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase MERCK FROSST CANADA LTD. (CA) 2009-11-26 US disclosed
US-20090118296-A1 Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase MERCK FROSST CANADA LTD. (CA) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN GRM5 1347/4885GPR119 846/4885SFRP1 4164/4885
US-20090291955-A1 Azacyclohexane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase SCD, SCD5, SREBF1 GRM5 2598/4885GPR119 73/4885SFRP1 2258/4885
US-20090118296-A1 Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase SCD, SCD5, SREBF1 GRM5 2497/4885GPR119 65/4885SFRP1 2585/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN GRM5 1347/4885GPR119 846/4885SFRP1 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.